Rhumbline Advisers Has $19.07 Million Position in DaVita HealthCare Partners Inc. (DVA)

Rhumbline Advisers boosted its stake in DaVita HealthCare Partners Inc. (NYSE:DVA) by 4.4% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 321,155 shares of the company’s stock after purchasing an additional 13,471 shares during the quarter. Rhumbline Advisers owned about 0.17% of DaVita HealthCare Partners worth $19,073,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of DVA. Migdal Insurance & Financial Holdings Ltd. acquired a new position in DaVita HealthCare Partners in the third quarter valued at about $154,000. Pzena Investment Management LLC raised its stake in DaVita HealthCare Partners by 2.1% during the second quarter. Pzena Investment Management LLC now owns 3,398 shares of the company’s stock worth $220,000 after acquiring an additional 71 shares in the last quarter. Eqis Capital Management Inc. raised its stake in DaVita HealthCare Partners by 2.2% during the second quarter. Eqis Capital Management Inc. now owns 4,600 shares of the company’s stock worth $298,000 after acquiring an additional 100 shares in the last quarter. Thrivent Financial For Lutherans raised its stake in DaVita HealthCare Partners by 4.4% during the first quarter. Thrivent Financial For Lutherans now owns 5,730 shares of the company’s stock worth $389,000 after acquiring an additional 240 shares in the last quarter. Finally, Jensen Investment Management Inc. raised its stake in DaVita HealthCare Partners by 24.2% during the second quarter. Jensen Investment Management Inc. now owns 9,740 shares of the company’s stock worth $631,000 after acquiring an additional 1,900 shares in the last quarter. 86.37% of the stock is owned by institutional investors and hedge funds.

Shares of DaVita HealthCare Partners Inc. (NYSE DVA) opened at $54.76 on Tuesday. The firm has a market capitalization of $10,500.00, a PE ratio of 15.69, a PEG ratio of 11.07 and a beta of 0.98. The company has a debt-to-equity ratio of 1.79, a quick ratio of 1.35 and a current ratio of 1.40. DaVita HealthCare Partners Inc. has a twelve month low of $52.51 and a twelve month high of $70.16.

DaVita HealthCare Partners (NYSE:DVA) last announced its earnings results on Tuesday, November 7th. The company reported $0.81 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.94 by ($0.13). DaVita HealthCare Partners had a net margin of 3.40% and a return on equity of 13.31%. The company had revenue of $3.92 billion during the quarter, compared to the consensus estimate of $3.91 billion. During the same quarter in the previous year, the company earned $0.95 earnings per share. The business’s revenue was up 5.2% on a year-over-year basis. research analysts anticipate that DaVita HealthCare Partners Inc. will post 3.42 EPS for the current year.

DaVita HealthCare Partners announced that its Board of Directors has approved a stock buyback plan on Tuesday, October 10th that authorizes the company to repurchase $1.50 billion in outstanding shares. This repurchase authorization authorizes the company to purchase shares of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s board of directors believes its stock is undervalued.

Several research analysts have commented on DVA shares. TheStreet downgraded DaVita HealthCare Partners from a “b” rating to a “c+” rating in a research note on Wednesday, August 2nd. Zacks Investment Research upgraded DaVita HealthCare Partners from a “sell” rating to a “hold” rating in a report on Thursday, August 3rd. Jefferies Group LLC restated a “hold” rating and set a $70.00 price target on shares of DaVita HealthCare Partners in a report on Thursday, August 3rd. Royal Bank Of Canada restated a “hold” rating and set a $64.00 price target on shares of DaVita HealthCare Partners in a report on Wednesday, September 6th. Finally, KeyCorp restated a “hold” rating on shares of DaVita HealthCare Partners in a report on Tuesday, October 10th. Four investment analysts have rated the stock with a sell rating, six have issued a hold rating and one has given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $63.00.

ILLEGAL ACTIVITY WARNING: This article was first published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this article on another website, it was illegally stolen and reposted in violation of international trademark & copyright laws. The legal version of this article can be accessed at https://ledgergazette.com/2017/11/21/rhumbline-advisers-has-19-07-million-position-in-davita-healthcare-partners-inc-dva.html.

About DaVita HealthCare Partners

DaVita Inc, formerly DaVita HealthCare Partners Inc, operates two divisions: DaVita Kidney Care (Kidney Care) and DaVita Medical Group (DMG). The Kidney Care division consists of its the United States dialysis and related lab services, its ancillary services and strategic initiatives, including its international operations, and its corporate administrative support.

Want to see what other hedge funds are holding DVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DaVita HealthCare Partners Inc. (NYSE:DVA).

Institutional Ownership by Quarter for DaVita HealthCare Partners (NYSE:DVA)

Receive News & Ratings for DaVita HealthCare Partners Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita HealthCare Partners Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply